PYLOPASS™ – A NEW APPROACH IN HELICOBACTER PYLORI CONTROL

 

pylopass trademark

Helicobacter pylori is a gram-negative, spiral shaped bacteria that colonizes the stomach and can cause gastritis and peptic ulcers. H. pylori infection may be asymptomatic before clinical symptoms develop. An estimated 50% of the worldwide population is infected with H. pylori. The highest prevalence is in countries with rapidly developing economies, such as Africa, Latin America, Southeast Asia and the Indian subcontinent, where the prevalence is estimated to be upwards of 90 percent. H. pylori is the leading cause of peptic ulcer disease and if untreated, can lead to gastric cancer. Eradication therapy is not recommended for all populations that are infected with H. pylori. The Maastricht IV/Florence Concensus Report for H. pylori treatment indicates that those with clinical symptoms such as peptic ulcer or risk factors such as first degree relation to a gastric cancer patient should seek eradication therapy with antibiotics.

Pylopass™ is a proprietary strain of Lactobacillus reuteri which specifically co-aggregates with Helicobacter pylori in the stomach to reduce the bacterial load. Pylopass™ is comprised of spray-dried L. reuteri cells and is stable in a wide range of applications for the end consumer market. Due to the stable nature of Pylopass™, it does not need to be refrigerated and can be used as a dietary supplement, in powdered beverages and in fermented dairy products.

For more information about Pylopass™, please contact our team.

coaggregation (2).jpg

 

 

 

 

 

Keterangancoaggregation (1)

 

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>